BROOKE STINEBAUGH: Open Payments
NPI 1629850748 · ABERDEEN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$357 in 17 payments from 9 companies in 2025. Trend: 2023 $58 · 2024 $1,199 · 2025 $357
Food & beverage: $357
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 6 | $106 |
| ABBVIE INC. | 3 | $73 |
| AstraZeneca Pharmaceuticals LP | 2 | $51 |
| Dexcom, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $21 |
| PFIZER INC. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $15 |
Products named: EVENITY, OTEZLA, QULIPTA, VRAYLAR, FARXIGA, Dexcom G6 Transmitter, AIRSUPRA, VOQUEZNA.
Industry payments across MD — which companies pay providers there.
